Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. Seo (Daegu, Republic of Korea), H. Kang (Daegu, Republic of Korea), D. Jung (Daegu, Republic of Korea), J. Choi (Daegu, Republic of Korea), H. Park (Daegu, Republic of Korea), H. Lee (Daegu, Republic of Korea), H. Oh (Daegu, Republic of Korea), Y. Lee (Daegu, Republic of Korea), S. Choi (Daegu, Republic of Korea), S. Yoo (Daegu, Republic of Korea), S. Lee (Daegu, Republic of Korea), J. Lee (Daegu, Republic of Korea), S. Cha (Daegu, Republic of Korea), C. Kim (Daegu, Republic of Korea), J. Park (Daegu, Republic of Korea). A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer. 3301

Member's Comments

No comment yet.

Related content which might interest you: MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 482s Year: 2005 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009